Streptococcus pneumoniae infection suppresses allergic airways disease by inducing regulatory T-cells

European Respiratory Journal

Volumn 37, Issue 1, 2011, Pages 53-64

  Preston, J A ^a   Thorburn, A N ^a   Starkey, M R ^a   Beckett, E L ^a   Horvat, J C ^a   Wade, M A ^a   O'Sullivan, B J ^b   Thomas, R ^b   Beagley, K W ^a,c   Gibson, P G ^a   Foster, P S ^a   Hansbro, P M ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Allergic airways disease; Asthma; Immune modulation; Regulatory T cell; Streptococcus pneumoniae; Suppression

Indexed keywords

AIRWAY; ALLERGIC DISEASE; ALLERGIC REACTION; ALLERGY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; ASTHMA; BACTERIAL INFECTION; CELL COUNT; CELL HYPERPLASIA; CELL PROLIFERATION; CYTOKINE RELEASE; EOSINOPHIL; GOBLET CELL; HELPER CELL; IMMUNE RESPONSE; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OOCYTE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; SENSITIZATION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TH2 CELL;

ANIMALS; ASTHMA; BRONCHIAL HYPERREACTIVITY; HUMANS; HYPERSENSITIVITY; IMMUNE SYSTEM; INFLAMMATION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LUNG; MICE; MICE, INBRED BALB C; RESPIRATORY HYPERSENSITIVITY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 79251540548     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00049510     Document Type: Article

References (29)

1. Australian Centre for Asthma Monitoring. Asthma in Australia. Canberra, Australian Institute for Health and Welfare, 2008.
2. Asher M, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368: 733-743.
3. Temelkovski J, Hogan S, Shepherd D, et al. An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax 1998; 53: 849-856.
4. Zuany-Amorim C, Sawicka E, Manlius C, et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med 2002; 8: 625-629.
5. Holt P, Upham J, Sly P. Contemporaneous maturation of immunologic and respiratory functions during early childhood: implications for development of asthma prevention strategies. J Allergy Clin Immunol 2005; 116: 16-24.
6. Hansbro P, Beagley K, Horvat J, et al. Role of atypical bacterial infection of the lung in predisposition/protection of asthma. Pharmacol Ther 2004; 101: 193-210.
7. Hansbro N, Horvat J, Wark P, et al. Understanding the mechanisms of viral induced asthma; new therapeutic directions. Pharmacol Ther 2008; 117: 313-353.
8. Horvat J, Starkey M, Kim R, et al. Early life chlamydial lung infection predisposes to allergic airways disease through age-dependent differences in immunopathology. J Allergy Clin Immunol 2010; 125: 617-625.
9. Culley F, Pollott J, Openshaw P. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med 2002; 196: 1381-1386.
10. Goldman D, Davis J, Bommarito F, et al. Enhanced allergic inflammation and airway responsiveness in rats with chronic Cryptococcus neoformans infection: potential role for fungal pulmonary infection in the pathogenesis of asthma. J Infect Dis 2006; 193: 1178-1186.
11. Thorburn A, Hansbro P. Harnessing regulatory T cells to suppress asthma: from potential to therapy. Am J Respir Cell Mol Biol 2010; 43: 511-519.
12. Shirtcliffe P, Easthope S, Cheng S, et al. The effect of delipidated deglycolipidated (DDMV) and heat-killed Mycobacterium vaccae in asthma. Am J Respir Crit Care Med 2001; 163: 1410-1414.
13. Arkwright P, David T. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol 2001; 107: 531-534.
14. Thorburn A, Hansbro P, Gibson P. Pneumococcal vaccines for allergic airways diseases. Expert Opin Biol Ther 2009; 9: 621-629.
15. Bass D. Behavior of eosinophil leukocytes in acute inflammation. I. Lack of dependence on adrenal function. J Clin Invest 1975; 55: 1229-1236.
16. Preston J, Essilfie A, Horvat J, et al. Inhibition of allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneumoniae. Vaccine 2007; 25: 8154-8162.
17. Horvat J, Starkey M, Kim R, et al. Chlamydial respiratory infection during allergen sensitization drives neutrophilic allergic airways disease. J Immunol 2010; 184: 4159-4169.
18. Malley R, Henneke P, Morse S, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003; 100: 1966-1971.
19. Leech M, Benson R, De Vries A, et al. Resolution of Der p1-induced allergic airway inflammation is dependent on CD4+CD25+Foxp3+ regulatory cells. J Immunol 2007; 179: 7050-7058.
20. O'Sullivan B, Thomas H, Pai S, et al. IL-1 beta breaks tolerance through expansion of CD25+ effector T cells. J Immunol 2006; 176: 7278-7287.
21. Quinn K, McHugh R, Rich F, et al. Inactivation of CD4+ CD25+ regulatory T cells during early mycobacterial infection increases cytokine production but does not affect pathogen load. Immunol Cell Biol 2006; 84: 467-474.
22. Preston J, Beagley K, Gibson P, et al. Genetic background affects susceptibility in non-fatal pneumococcal bronchopneumonia. Eur Respir J 2004; 23: 224-231.
23. Kaiko G, Horvat J, Beagley K, et al. Immunological decision-making: How does the immune system decide to mount either a Th1 or Th2 response? Immunology 2008; 123: 326-338.
24. Kumar R, Herbert C, Foster P. The "classical" ovalbumin model of asthma in mice. Curr Drug Targets 2008; 9: 485-494.
25. Mattes J, Yang M, Mahalingam S, et al. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med 2002; 195: 1433-1444.
26. Humbles A, Lloyd C, McMillan S, et al.A critical role for eosinophils in allergic airways remodeling. Science 2004; 305: 1776-1779.
27. Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003; 111: 714-719.
28. Kadioglu A, Coward W, Colston M, et al. CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect Immun 2004; 72: 2689-2697.
29. Kearley J, Barker J, Robinson D, et al. Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. J Exp Med 2005; 202: 1539-1547.